

Cell specificity and properties of the C-3 epimerization of Vitamin D₃ metabolites[☆]

Maya Kamao^a, Syuichiro Tatematsu^a, Natsumi Sawada^b, Toshiyuki Sakaki^b,
Susumi Hatakeyama^c, Noboru Kubodera^d, Toshio Okano^{a,*}

^a Department of Hygienic Sciences, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan

^b Laboratory of Enzyme Chemistry, Kyoto University, Kitasirakawa, Sakyo-ku, Kyoto 606-8502, Japan

^c Faculty of Pharmaceutical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan

^d Chugai Pharmaceutical Co. Ltd., Tokyo, 2-1-9 Kyobashi, Chuo-ku, Tokyo 104-0031, Japan

Abstract

It is well documented that Vitamin D₃ metabolites and synthetic analogs are metabolized to their epimers of the hydroxyl group at C-3 of the A-ring. We investigated the C-3 epimerization of Vitamin D₃ metabolites in various cultured cells and basic properties of the enzyme responsible for the C-3 epimerization. 1 α ,25-Dihydroxyvitamin D₃ [1 α ,25(OH)₂D₃], 25-hydroxyvitamin D₃ [25(OH)D₃] and 24,25-dihydroxyvitamin D₃ [24,25(OH)₂D₃] were metabolized to the respective C-3 epimers in UMR-106 (rat osteosarcoma), MG-63 (human osteosarcoma), Caco-2 (human colon adenocarcinoma), LLC-PK₁ (porcine kidney) and HepG2 (human hepatoblastoma) cells, although the differences existed in the amount of each C-3 epimer formed with different cell types. In terms of maximum velocity (V_{\max}) and Michaelis constant (K_m) values for the C-3 epimerization in microsome fraction of UMR-106 cells, 25(OH)D₃ exhibited the highest specificity for the C-3 epimerization among 1 α ,25(OH)₂D₃, 25(OH)D₃ and 24,25(OH)₂D₃. C-3 epimerization activity was not inhibited by various cytochrome P450 inhibitors and antiserum against NADPH cytochrome P450 reductase. Neither CYP24, CYP27A1, CYP27B1 nor 3($\alpha \rightarrow \beta$)-hydroxysteroid epimerase (HSE) catalyzed the C-3 epimerization *in vitro*. Based on these results, the enzyme responsible for the C-3 epimerization of Vitamin D₃ are thought to be different from already-known cytochrome P450-related Vitamin D metabolic enzymes and HSE.

© 2004 Elsevier Ltd. All rights reserved.

Keywords: C-3 Epimerization; Cell specificity; Enzymatic properties; Vitamin D metabolism; 1 α ,25-Dihydroxyvitamin D₃; 25-Hydroxyvitamin D₃; 24,25-Dihydroxyvitamin D₃

1. Introduction

25-Hydroxyvitamin D₃ [25(OH)D₃] and 1 α ,25-dihydroxyvitamin D₃ [1 α ,25(OH)₂D₃] are metabolized via C-24 or C-23/26 oxidation pathways by 25-hydroxyvitamin D₃ 24-hydroxylase (24OHase, CYP24). Recently, a novel A-ring modification metabolic pathway of 1 α ,25(OH)₂D₃ was identified in a human colon adenocarcinoma-derived cell line [1] and other cultured cells [2], which is initiated by epimerization of the hydroxyl group at C-3 of the A-ring. 3-Epi-1 α ,25(OH)₂D₃ was also identified as a circulating metabolite of 1 α ,25(OH)₂D₃ in rats treated with pharmacological doses of 1 α ,25(OH)₂D₃ [3]. 3-Epi-1 α ,25(OH)₂D₃ was almost equipotent to 1 α ,25(OH)₂D₃ in suppressing parathyroid hormone secretion [4] and more potent than

1 α ,25(OH)₂D₃ in inducing HL-60 cell apoptosis [5] regardless of lower VDR binding affinity and weak regulatory activities of cell proliferation and differentiation. 25(OH)D₃, 24,25-dihydroxyvitamin D₃ [24,25(OH)₂D₃] [6,7] and the synthetic analog, 22-oxacalcitriol [22-oxa-1 α ,25(OH)₂D₃, OCT] [8] were also metabolized through the C-3 epimerization pathway. However, little is known about the biological significance of the C-3 epimerization pathway and its related enzyme(s). We performed experiments to characterize the C-3 epimerization of Vitamin D₃ metabolites in various cultured cells and basic enzymatic properties.

2. Materials and methods

2.1. Measurement of C-3 epimerization activity in cultured cells

UMR-106 (rat osteosarcoma), MG-63 (human osteosarcoma), Caco-2 (human colon adenocarcinoma), LLC-PK₁

[☆] Presented at the 12 Workshop on Vitamin D (Maastricht, The Netherlands, 6–10 July 2003).

* Corresponding author. Tel.: +81-78-441-7563; fax: +81-78-441-7565.
E-mail address: t-okano@kobepharm-u.ac.jp (T. Okano).

(porcine kidney) and HepG2 (human hepatoblastoma) cells were incubated with 10 μM of $1\alpha,25(\text{OH})_2\text{D}_3$, $25(\text{OH})\text{D}_3$ or $24,25(\text{OH})_2\text{D}_3$ for 48 h at 37 °C. Lipid was extracted from cells and medium by methanol and dichloromethane. The lipid-soluble metabolites were purified by HPLC with photodiode array detector [Zorbax SIL, hexane:2-propanol:methanol (88:10:2), 1.0 ml/min]. The same metabolites were also separated by second HPLC system [Sumichiral OA-2000, 2-propanol:hexane (96.5:3.5 or 94.5:5.5), 1.0 ml/min].

2.2. Measurement of C-3 epimerization activity in microsomal fraction of UMR-106 cells

The microsomal fraction containing 4.0 mg of protein prepared from UMR-106 cells were incubated with $1\alpha,25(\text{OH})_2\text{D}_3$, $25(\text{OH})\text{D}_3$ or $24,25(\text{OH})_2\text{D}_3$ in the presence of NADPH-generating reagents consisting of 10 μmol of NADP, 70 μmol of glucose 6-phosphate, 12 IU of glucose-6-phosphate dehydrogenase and 100 μmol of Mg^{2+} in 50 mM potassium phosphate buffer (pH 6.5) for 1 h at 37 °C. Generated amounts of C-3 epimers were measured by HPLC and V_{max} and K_{m} values were calculated from Lineweaver–Burk plot. The effect of various cytochrome P450 inhibitors (20 μM) or antiserum against NADPH cytochrome P450 reductase was also examined.

2.3. Measurement of C-3 epimerization activity in expression systems of human CYP24, CYP27A1, CYP27B1 and HSE

The expression plasmids for human CYP24 [9], CYP27A1 [10] or CYP27B1 [11] were constructed, transfected to *Escherichia coli* cells and the membrane fractions of recombinant *E. coli* cells were prepared. The C-3 epimerization activity for $25(\text{OH})\text{D}_3$ was measured in reconstituted system consisting of the membrane fractions and 0.5 mmol of NADPH in 100 mM Tris–HCl buffer (pH 7.4) for 1 h at 37 °C. Cos-7 (African green monkey kidney, SV40-transformed) cells were transfected with the expression vector pcDNA 3.1 (–)- $3(\alpha \rightarrow \beta)$ -hydroxysteroid epimerase (HSE) [12] and incubated with $25(\text{OH})\text{D}_3$, 3-epi- $25(\text{OH})\text{D}_3$, androsterone or epi-androsterone for 48 h at 37 °C. The metabolites were separated by HPLC or TLC.

3. Results

3.1. Cell specificity of the C-3 epimerization of Vitamin D₃ metabolite in cultured cells

All the cells exhibited the C-3 epimerization of $1\alpha,25(\text{OH})_2\text{D}_3$, $25(\text{OH})\text{D}_3$ and $24,25(\text{OH})_2\text{D}_3$, although $25(\text{OH})\text{D}_3$ was also metabolized to $24,25(\text{OH})_2\text{D}_3$ beside 3-epi- $25(\text{OH})\text{D}_3$ (Fig. 1). The C-3 epimerization activity for




Fig. 1. Relative generated amounts of $25(\text{OH})\text{D}_3$ metabolites in UMR-106, MG-63, Caco-2, LLC-PK₁ and HepG2 cells. Each of the cells were incubated with 10 μM of $25(\text{OH})\text{D}_3$ for 48 h. The results are expressed as the total amount of product formed in $\mu\text{g}/\text{plate}/48\text{ h}$ and represent the mean of three experiments (values in column).

$24,25(\text{OH})_2\text{D}_3$ was commonly lower than that of $25(\text{OH})\text{D}_3$ and $1\alpha,25(\text{OH})_2\text{D}_3$ in all the cells tested. In UMR-106, MG-63, Caco-2 and HepG2 cells, 3-epi- $25(\text{OH})\text{D}_3$ was predominantly generated, whereas $24,25(\text{OH})_2\text{D}_3$ was the most major metabolite in LLC-PK₁ cells. HepG2 cells was the most active among the cells to metabolize $25(\text{OH})\text{D}_3$ to 3-epi- $25(\text{OH})\text{D}_3$ and the generated amount of 3-epi- $25(\text{OH})\text{D}_3$ was about eight-fold larger than that of $24,25(\text{OH})_2\text{D}_3$.

3.2. Basic properties of C-3 epimerization in microsomal fraction of UMR-106 cells

In the microsomal fraction of UMR-106 cells, V_{max} values for $1\alpha,25(\text{OH})_2\text{D}_3$, $25(\text{OH})\text{D}_3$ and $24,25(\text{OH})_2\text{D}_3$ were 1.52, 2.34 and 0.51 pmol/min/mg protein, respectively (Table 1). K_{m} values for $1\alpha,25(\text{OH})_2\text{D}_3$, $25(\text{OH})\text{D}_3$ and $24,25(\text{OH})_2\text{D}_3$ were 98.9, 73.7 and 200.1 μM , respectively. These results indicate that $25(\text{OH})\text{D}_3$ is the substrate with the highest specificity for the C-3 epimerization reaction among the three metabolites. C-3 epimerization activity for $25(\text{OH})\text{D}_3$ was not inhibited by commonly used cytochrome P450 inhibitors (ketoconazole, 1-aminobenzotriazol, benzilimidazole, methoxalen, metyrapon and SKF-525A), CYP2D6 specific inhibitor (quinidine), CYP3A4 specific inhibitor (troleandomycin) and antiserum against NADPH cytochrome P450 reductase.

Table 1
Kinetic parameters for C-3 epimerization

Substrate	V_{max} (pmol/min/mg protein)	K_{m} (μM)	$V_{\text{max}}/K_{\text{m}}$ (pmol/min/mg protein/ μM)
$1\alpha,25(\text{OH})_2\text{D}_3$	1.52	98.9	0.015
$25(\text{OH})\text{D}_3$	2.34	73.7	0.032
$24,25(\text{OH})_2\text{D}_3$	0.51	200.1	0.0025




Fig. 2. C-3 epimerization pathway of major Vitamin D₃ metabolites.

3.3. C-3 epimerization activity in expression systems of human CYP24, CYP27A1, CYP27B1 and HSE

In the reconstituted system containing the membrane fractions prepared from the *E. coli* expressing CYP24, CYP27A1 or CYP27B1, 25(OH)D₃ was metabolized to 1α,25(OH)₂D₃ or 24,25(OH)₂D₃. However, the generation of 3-epi-25(OH)D₃ was not observed in all the systems tested. In Cos-7 cells transfected HSE expression vector, androsterone (3α) and epi-androsterone (3β) were converted to epi-androsterone (3β) and androsterone (3α), respectively. However, C-3 epimerization of 25(OH)D₃ was not changed in the HSE transfected Cos-7 cells when compared to the Cos-7 cells transfected with the expression vector only.

4. Discussion

The present study clearly indicate that UMR-106, MG-63, Caco-2, LLC-PK₁ and HepG2 cells possess the ability to metabolize 1α,25(OH)₂D₃, 25(OH)D₃ and 24,25(OH)₂D₃ to their C-3 epimers (Fig. 2). Thus, the C-3 epimerization appears to be a common metabolic pathway for the major Vitamin D₃ metabolites and may play an important role in the regulation of Vitamin D₃ metabolism. We also demonstrated that 25(OH)D₃ was better substrate for C-3 epimerization than 1α,25(OH)₂D₃ and 24,25(OH)₂D₃. From this finding, it appears that the enzyme responsible for the C-3 epimerization can recognize the differences in the side chain and the A-ring structure of Vitamin D. In addition, since C-3 epimerization was not catalyzed by CYP24, CYP27A1, CYP27B1 and HSE, the C-3 epimerization enzyme for Vitamin D₃

metabolites are thought to be different from already-known cytochrome P450-related Vitamin D metabolic enzymes and HSE.

Acknowledgements

This work was supported in part by a grants-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan, a Grant for Cooperative Research administered by the Japan Private School Promotion Foundation and a grant-in-aid from the Ministry of Health and Welfare of Japan.

References

- [1] M.G. Bischof, M.-L. Siu-Caldera, A. Weiskopf, P. Vouros, H.S. Cross, M. Peterlok, G.S. Reddy, Differentiation-related pathways of 1α,25-dihydroxycholecalciferol metabolism in human colon adenocarcinoma-derived Caco-2 cells: production of 1α,25-dihydroxy-3-epi-cholecalciferol, *Exp. Cell. Res.* 241 (1998) 194–201.
- [2] S. Masuda, M. Kamao, N.J. Schroeder, H.L.J. Makin, G. Jones, R. Kremer, J. Rhim, T. Okano, Characterization of 3-epi-1α,25-dihydroxyvitamin D₃ involved in 1α,25-dihydroxyvitamin D₃ metabolic pathway in cultured cell lines, *Biol. Pharm. Bull.* 23 (2000) 133–139.
- [3] H. Sekimoto, M.-L. Siu-Caldera, A. Weiskopf, P. Vouros, K.R. Muralidharan, W.H. Okamura, M.R. Uskokovic, G.S. Reddy, 1α,25-Dihydroxy-3-epi-vitamin D₃: in vivo metabolite of 1α,25-dihydroxyvitamin D₃ in rats, *FEBS Lett.* 448 (1999) 278–282.
- [4] A.J. Brown, C. Ritter, E. Slatopolsky, K.R. Muralidharan, W.H. Okamura, G.S. Reddy, 1α,25-dihydroxy-3-epi-vitamin D₃, a natural metabolite of 1α,25-dihydroxyvitamin D₃, is a potent suppressor of parathyroid hormone secretion, *J. Cell Biochem.* 73 (1999) 106–113.
- [5] K. Nakagawa, Y. Sowa, M. Kurobe, K. Ozono, M.-L. Siu-Caldera, G.S. Reddy, M.R. Uskokovic, T. Okano, Differential activities of

- $1\alpha,25$ -dihydroxy-16-ene-vitamin D_3 analogs and their 3-epimers on human promyelocytic leukemia (HL-60) cell differentiation and apoptosis, *Steroids* 66 (2001) 327–337.
- [6] T. Higashi, R. Kikuchi, K. Miura, K. Shimada, H. Hiyamizu, H. Ooi, Y. Iwabuchi, S. Hatakeyama, N. Kubodera, New metabolic pathway of (24R)-24,25-dihydroxyvitamin D_3 : epimerization of the 3-hydroxy group, *Biol. Pharm. Bull.* 22 (1999) 767–769.
- [7] M. Kamao, S. Tatematsu, G.S. Reddy, S. Hatakeyama, M. Sugiura, N. Ohashi, N. Kubodera, T. Okano, Isolation, identification and biological activity of 24R,25-dihydroxy-3-epi-vitamin D_3 : a novel metabolite of 24R,25-dihydroxyvitamin D_3 produced in rat osteosarcoma cells (UMR 106), *J. Nutr. Sci. Vitaminol.* 47 (2001) 108–115.
- [8] M. Kamao, S. Tatematsu, S. Hatakeyama, K. Ozono, N. Kubodera, G.S. Reddy, T. Okano, Two novel metabolic pathways of 22-oxacalcitriol (OCT), *J. Biol. Chem.* 278 (2003) 1463–1471.
- [9] T. Sakaki, N. Sawada, K. Komai, S. Shiozawa, S. Yamada, K. Yamamoto, Y. Ohyama, K. Inoue, Dual metabolic pathway of 25-hydroxyvitamin D_3 catalyzed by human CYP24, *Eur. J. Biochem.* 267 (2000) 6158–6165.
- [10] N. Sawada, T. Sakaki, M. Ohta, K. Inoue, Metabolism of Vitamin D_3 by human CYP27A1, *Biochem. Biophys. Res. Commun.* 273 (2000) 977–984.
- [11] N. Sawada, T. Sakaki, S. Kitanaka, K. Takeyama, S. Kato, K. Inoue, Enzymatic properties of human 25-hydroxyvitamin D_3 1α -hydroxylase, *Eur. J. Biochem.* 265 (1999) 950–956.
- [12] X.-F. Huang, V. Luu-The, Molecular characterization of a first human $3(\alpha \rightarrow \beta)$ -hydroxysteroid epimerase, *J. Biol. Chem.* 275 (2000) 29452–29457.